Catheter ablation for atrial fibrillation in patients with chronic kidney disease and on dialysis – a meta-analysis and review

Research Article

Open Access Gateway Chung I. · Khan Y. · Warrens H. · Seshasai R.K. · Sohal M. · Banerjee D.
Abstract

Background: Atrial fibrillation (AF) is common in chronic kidney disease (CKD) patients and is difficult to treat with antiarrhythmics and anticoagulants due to abnormal metabolism and increased side effects. Catheter ablation, if successful, may be a safer alternative. This review aims to analyse the effect of CKD or haemodialysis (HD) on recurrence of AF after catheter ablation . This review evaluates efficacy of catheter ablation therapy in CKD and haemodialysis (HD) patients by with single catheter ablation therapy. Methods: MEDLINE, and Embase, and Pubmed databases were searched until December 2020. Two authors abstracted the data independently. Relative risks were derived using random-effects meta-analysis. Results: Of the initially identified 520 782 studies, 65 and 34 observational studies on CKD and HD patients respectively were found reporting AF recurrence rates. During a mean (SD) follow-up of 25.5 (9.8) months, CKD patients have a higher risk of AF recurrence compared to patients without CKD (RR 2.34, 95% CI 1.36-4.02, p

The Author(s). Published by S. Karger AG, Basel

Article / Publication Details Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif